Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment

BACKGROUND/AIMS: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start biologics after anti-HBV treatment. We investigated the risk of HBV reactivation according to the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Soo Min, Choi, Jonggi, Ye, Byong Duk, Yang, Suk-Kyun, Oh, Ji Seon, Kim, Yong-Gil, Lee, Chang-Keun, Yoo, Bin, Park, Sang Hyoung, Hong, Seokchan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289826/
https://www.ncbi.nlm.nih.gov/pubmed/34840146
http://dx.doi.org/10.5009/gnl210204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289826/
https://www.ncbi.nlm.nih.gov/pubmed/34840146
http://dx.doi.org/10.5009/gnl210204

Ejemplares similares